drugset / Trial / NCT07407543
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males
RandomizedSequentialQuadruple-blindTreatment
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.
Timeline
- Start
- 2026-01-05
- Primary completion
- 2026-10-31
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SRN001 | Small interfering RNA (siRNA) | 45 mg | — |
| Subject | SRN001 | Small interfering RNA (siRNA) | 90 mg | — |
| Subject | SRN001 | Small interfering RNA (siRNA) | 180 mg | — |